Pseudomonas aeruginosa: host defence in lung diseases
- PMID: 20723140
- DOI: 10.1111/j.1440-1843.2010.01819.x
Pseudomonas aeruginosa: host defence in lung diseases
Abstract
Lung infections caused by the opportunistic pathogen Pseudomonas aeruginosa can present as a spectrum of clinical entities from a rapidly fatal pneumonia in a neutropenic patient to a multi-decade bronchitis in patients with cystic fibrosis. P. aeruginosa is ubiquitous in our environment, and one of the most versatile pathogens studied, capable of infecting a number of diverse life forms and surviving harsh environmental factors. It is also able to quickly adapt to new environments, including the lung, where it orchestrates virulence factors to acquire necessary nutrients, and if necessary, turn them off to prevent immune recognition. Despite these capabilities, P. aeruginosa rarely infects healthy human lungs. This is secondary to a highly evolved host defence mechanism that efficiently removes inhaled or aspirated pseudomonads. Many arms of the respiratory host defence have been elucidated using P. aeruginosa as a model pathogen. Human infections with P. aeruginosa have demonstrated the importance of the mechanical barrier functions including mucus clearance, and the innate immune system, including the critical role of the neutrophilic response. As more models of persistent or biofilm P. aeruginosa infections are developed, the role of the adaptive immune response will likely become more evident. Understanding the pathogenesis of P. aeruginosa, and the respiratory host defence response to it has, and will continue to, lead to novel therapeutic strategies to help patients.
© 2010 The Authors. Respirology © 2010 Asian Pacific Society of Respirology.
Similar articles
-
Pseudomonas aeruginosa in chronic lung disease: untangling the dysregulated host immune response.Front Immunol. 2024 Jun 28;15:1405376. doi: 10.3389/fimmu.2024.1405376. eCollection 2024. Front Immunol. 2024. PMID: 39015565 Free PMC article. Review.
-
The Small RNA ErsA Plays a Role in the Regulatory Network of Pseudomonas aeruginosa Pathogenicity in Airway Infections.mSphere. 2020 Oct 14;5(5):e00909-20. doi: 10.1128/mSphere.00909-20. mSphere. 2020. PMID: 33055260 Free PMC article.
-
Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface.Clin Microbiol Rev. 2019 May 29;32(3):e00138-18. doi: 10.1128/CMR.00138-18. Print 2019 Jun 19. Clin Microbiol Rev. 2019. PMID: 31142499 Free PMC article. Review.
-
Polymorphonuclear leukocytes restrict growth of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients.Infect Immun. 2014 Nov;82(11):4477-86. doi: 10.1128/IAI.01969-14. Epub 2014 Aug 11. Infect Immun. 2014. PMID: 25114118 Free PMC article.
-
Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection.J Med Microbiol. 2003 Sep;52(Pt 9):731-740. doi: 10.1099/jmm.0.05122-0. J Med Microbiol. 2003. PMID: 12909647
Cited by
-
Pseudomonas aeruginosa Bacteriophages and Their Clinical Applications.Viruses. 2024 Jun 29;16(7):1051. doi: 10.3390/v16071051. Viruses. 2024. PMID: 39066214 Free PMC article. Review.
-
Lipoxygenases at the Intersection of Infection and Carcinogenesis.Int J Mol Sci. 2024 Apr 2;25(7):3961. doi: 10.3390/ijms25073961. Int J Mol Sci. 2024. PMID: 38612771 Free PMC article. Review.
-
Pseudomonas aeruginosa: Infections and novel approaches to treatment "Knowing the enemy" the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment.Infect Med (Beijing). 2023 May 26;2(3):178-194. doi: 10.1016/j.imj.2023.05.003. eCollection 2023 Sep. Infect Med (Beijing). 2023. PMID: 38073886 Free PMC article. Review.
-
Microbiota Profile of the Nasal Cavity According to Lifestyles in Healthy Adults in Santiago, Chile.Microorganisms. 2023 Jun 22;11(7):1635. doi: 10.3390/microorganisms11071635. Microorganisms. 2023. PMID: 37512807 Free PMC article.
-
PlyKp104, a Novel Phage Lysin for the Treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and Other Gram-Negative ESKAPE Pathogens.Antimicrob Agents Chemother. 2023 May 17;67(5):e0151922. doi: 10.1128/aac.01519-22. Epub 2023 Apr 26. Antimicrob Agents Chemother. 2023. PMID: 37098944 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials